WallStreetZenWallStreetZen

NASDAQ: MDGL
Madrigal Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for MDGL

Based on 6 analysts offering 12 month price targets for Madrigal Pharmaceuticals Inc.
Min Forecast
$224.00+5.11%
Avg Forecast
$304.67+42.96%
Max Forecast
$383.00+79.71%

Should I buy or sell MDGL stock?

Based on 6 analysts offering ratings for Madrigal Pharmaceuticals Inc.
Buy
Strong Buy
1 analysts 16.67%
Buy
4 analysts 66.67%
Hold
1 analysts 16.67%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their MDGL stock forecasts and price targets.

MDGL stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2023-11-14
lockedlocked$00.00+00.00%2023-11-13
lockedlocked$00.00+00.00%2023-09-19
lockedlocked$00.00+00.00%2023-09-11
lockedlocked$00.00+00.00%2023-08-09
Canaccord Genuity
Bottom 11%
11
Strong BuyReiterates$336.00+65.27%2023-07-18

1 of 1

Forecast return on equity

Is MDGL forecast to generate an efficient return?
Company
N/A
Industry
-0.68%
Market
30.08%

Forecast return on assets

Is MDGL forecast to generate an efficient return on assets?
Company
N/A
Industry
-0.19%

MDGL revenue forecast

What is MDGL's revenue in the next 3 years based on estimates from 7 analysts?
Avg 1 year Forecast
$192.3M
Avg 2 year Forecast
$614.6M
Avg 3 year Forecast
$1.3B

MDGL vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
MDGL$203.30$304.67+49.86%Buy
MRTX$56.75$59.14+4.22%Buy
NUVL$65.37$60.50-7.45%Strong Buy
BPMC$69.64$73.33+5.30%Buy
ACAD$22.28$33.33+49.61%Buy
View Top Biotech Stocks

Madrigal Pharmaceuticals Stock Forecast FAQ

Is Madrigal Pharmaceuticals Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: MDGL) stock is to Buy MDGL stock.

Out of 6 analysts, 1 (16.67%) are recommending MDGL as a Strong Buy, 4 (66.67%) are recommending MDGL as a Buy, 1 (16.67%) are recommending MDGL as a Hold, 0 (0%) are recommending MDGL as a Sell, and 0 (0%) are recommending MDGL as a Strong Sell.

If you're new to stock investing, here's how to buy Madrigal Pharmaceuticals stock.

What is MDGL's revenue growth forecast for 2024-2026?

(NASDAQ: MDGL) Madrigal Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 33.88%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.51%.

Madrigal Pharmaceuticals's revenue in 2023 is $0.On average, 7 Wall Street analysts forecast MDGL's revenue for 2024 to be $3,795,958,032, with the lowest MDGL revenue forecast at $1,708,923,438, and the highest MDGL revenue forecast at $8,344,229,332. On average, 6 Wall Street analysts forecast MDGL's revenue for 2025 to be $12,134,185,599, with the lowest MDGL revenue forecast at $6,329,689,734, and the highest MDGL revenue forecast at $22,439,294,017.

In 2026, MDGL is forecast to generate $24,762,608,598 in revenue, with the lowest revenue forecast at $18,367,965,559 and the highest revenue forecast at $35,642,188,530.

What is MDGL's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: MDGL) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of -0.19%.

What is MDGL's Price Target?

According to 6 Wall Street analysts that have issued a 1 year MDGL price target, the average MDGL price target is $304.67, with the highest MDGL stock price forecast at $383.00 and the lowest MDGL stock price forecast at $224.00.

On average, Wall Street analysts predict that Madrigal Pharmaceuticals's share price could reach $304.67 by Nov 14, 2024. The average Madrigal Pharmaceuticals stock price prediction forecasts a potential upside of 49.86% from the current MDGL share price of $203.30.

What is MDGL's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: MDGL) forecast ROE is N/A, which is considered weak.
©2023 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.